Trial Profile
A multicenter, real-world study on two oral Truvada approaches to prevent HIV infection among MSM in China (CROPrEP)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Sep 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms CROPrEP
- 21 Jul 2021 Status changed from recruiting to completed.
- 21 Jul 2021 Primary endpoint has been met. (HIV incidence)
- 21 Jul 2021 Results presented at the 11th International AIDS Society Conference on HIV Science